Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs

Memorias do Instituto Oswaldo Cruz

Volumn 107, Issue 2, 2012, Pages 254-261

  Peres da Silva, Allan ^a   de Almeida, Adilson José ^a,b   Lampe, Elisabeth ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

Author keywords

Direct acting antiviral agents; Genetic diversity; Hepatitis C virus; NS3 protease

Indexed keywords

HEPATITIS C VIRUS;

EID: 84857956447     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762012000200016     Document Type: Article

References (34)

1. Alter MJ 2007. Epidemiology of hepatitis C virus infection. World J Gastroenterol 13: 2436-2441.
2. Anisimova M, Gascuel O 2006. Approximate likelihood-ratio test for branches: a fast, accurate and powerful alternative. Syst Biol 55: 539-552.
3. Asselah T, Marcellin P 2011. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int 31: 68-77.
4. Bae A, Sun SC, Qi X, Chen X, Ku K, Worth A, Wong KA, Harris J, Miller MD, Mo H 2010. Susceptibility of treatment-naïve hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother 54: 5288-5297.
5. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM 2009. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS ONE 4: e8209.
6. Enomoto M, Tamori A, Kawada N 2009. Emerging antiviral drugs for hepatitis C virus. Rev Recent Clin Trials 4: 179-184.
7. de Almeida AJ, Campos-de-Magalhães M, de Melo Marçal OP, Brandão-Mello CE, Okawa MY, de Oliveira RV, do Espírito-Santo MP, Yoshida CF, Lampe E 2004. Hepatitis C virus-associated thrombocytopenia: a controlled prospective, virological study. Ann Hematol 83: 434-440.
8. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, Gale M Jr 2003. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300: 1145-1148.
9. Guindon S, Gascuel O 2003. A simple, fast and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52: 696-704.
10. Korber B 2000. HIV signature and sequence variation analysis. In AG Rodrigo, GH Learn, Computational analysis of HIV molecular sequences, Kluwer Academic Publishers, Netherlands, p. 55-72.
11. Korber B, Myers G 1992. Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses 8: 1549-1560.
12. Kuiken C, Yusim K, Boykin L, Richardson R 2005. The Los Alamos hepatitis C sequence database. Bioinformatics 21: 379-384.
13. Lai CK, Jeng KS, Machida K, Cheng YS, Lai MM 2008. Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation. Virology 370: 295-309.
14. Lampe E, Espírito-Santo MP, Martins RM, Bello G 2010. Epidemic history of hepatitis C virus in Brazil. Infect Genet Evol 10: 886-895.
15. Lavanchy D 2009. The global burden of hepatitis C. Liver Int 29: 74-81.
16. López-Labrador FX 2008. Hepatitis C virus NS3/4A protease inhibitors. Recent Pat Antiinfect Drug Discov 3: 157-167.
17. López-Labrador FX, Moya A, González-Candelas F 2008. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 13: 481-494.
18. Mello IM, Thumann C, Schvoerer E, Soulier E, Pinho JR, Silvestre DA, Queiroz AT, Wolf P, Baumert TF, Keller FS, Pereira CA 2009. Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation. J Viral Hepat 16: 732-737.
19. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437: 1167-1172.
20. Murphy D, Chamberland J, Dandavino R, Sablon E 2007. A new genotype of hepatitis C vírus originating from Central Africa. Hepatology 46: 623A.
21. Nakamura M, Saito H, Hibi T 2008. Advances in genomic research on hepatitis C virus with a useful tool replicon system. Keio J Med 57: 75-83.
22. Nei M, Gojobori T 1986. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 3: 418-426.
23. Peres-da-Silva A, de Almeida AJ, Lampe E 2010. Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naïve patients. Arch Virol 155: 807-811.
24. Pickett BE, Striker R, Lefkowitz EJ 2011. Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat 18: 608-618.
25. Russo MW, Fried MW 2003. Side effects of therapy for chronic hepatitis C. Gastroenterology 124: 1711-1719.
26. Schinazi RF, Bassit L, Gavegnano C 2010. HCV drug discovery aimed at viral eradication. J Viral Hepat 17: 77-90.
27. Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, Holmes EC 1994. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol 75: 1053-1061.
28. Tamura K, Dudley J, Nei M, Kumar S 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
29. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG 1997. The CLUSTALX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.
30. Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia E, Ralston R 2008. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 77: 177-185.
31. Triyatni M, Berger EA, Saunier B 2011. A new model to produce infectious hepatitis C virus without the replication requirement. PLoS Pathog 7: e1001333.
32. Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, Farrior A, Sablon E, Jankowski-Hennig M, Schaper C, Johnson P, Van Ranst M, Van Brussel M 2008. Evaluation of versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 46: 1901-1906.
33. Vermehren J, Sarrazin C 2011. New HCV therapies on the horizon. Clin Microbiol Infect 17: 122-134.
34. Zeng R, Li G, Ling S, Zhang H, Yao Z, Xiu B, He F, Huang R, Wei L 2009. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. Antiviral Res 84: 23-30.